3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Dermatologic
2
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
6
Radiotherapy
5
olaparib
3
exemestane
3
Paclitaxel
3
Letrozole
3
Itraconazole
3
Gemcitabine
3
Fulvestrant
3
Carboplatin
3
Blood Specimen Collection
3
palbociclib
2
fludarabine phosphate
2
eribulin
2
avelumab
2
abemaciclib
2
Therapeutics
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Mastectomy
2
Flow Cytometry
2
Filgrastim
2
Exercise
2
Everolimus
2
Etoposide
2
Dasatinib
2
Cetuximab
2
Carmustine
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
bempegaldesleukin
×
Breast
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts